Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.
Svicher V, Cento V, Rozera G, Abbate I, Santoro MM, Armenia D, Fabeni L, Bruselles A, Latini A, Palamara G, Micheli V, Rizzardini G, Gori C, Forbici F, Ippolito G, Andreoni M, Antinori A, Ceccherini-Silberstein F, Capobianchi MR, Perno CF. Svicher V, et al. PLoS One. 2013;8(1):e53603. doi: 10.1371/journal.pone.0053603. Epub 2013 Jan 14. PLoS One. 2013. PMID: 23341955 Free PMC article.
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S, Svicher V, Ceccherini-Silberstein F, Cenci A, Marcuccilli F, Giannella S, Marcon L, Caliò R, Balzarini J, Perno CF. Aquaro S, et al. Among authors: svicher v. J Antimicrob Chemother. 2005 Jun;55(6):872-8. doi: 10.1093/jac/dki104. Epub 2005 Apr 21. J Antimicrob Chemother. 2005. PMID: 15845785
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher V, D'Arrigo R, Emberti-Gialloreti L, Ceffa S, Erba F, Marazzi MC, Silberstein FC, Perno CF. Bellocchi MC, et al. Among authors: svicher v. J Med Virol. 2005 Aug;76(4):452-8. doi: 10.1002/jmv.20382. J Med Virol. 2005. PMID: 15977236
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. Among authors: svicher v. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Therapeutic strategies towards HIV-1 infection in macrophages.
Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S. Perno CF, et al. Among authors: svicher v. Antiviral Res. 2006 Sep;71(2-3):293-300. doi: 10.1016/j.antiviral.2006.05.015. Epub 2006 Jun 9. Antiviral Res. 2006. PMID: 16806514 Review.
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.
Svicher V, Sing T, Santoro MM, Forbici F, Rodríguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. J Virol. 2006 Jul;80(14):7186-98. doi: 10.1128/JVI.02084-05. J Virol. 2006. PMID: 16809324 Free PMC article.
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Santoro MM, et al. Among authors: svicher v. New Microbiol. 2006 Apr;29(2):89-100. New Microbiol. 2006. PMID: 16841549
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. Aquaro S, et al. Among authors: svicher v. J Antimicrob Chemother. 2006 Oct;58(4):714-22. doi: 10.1093/jac/dkl306. Epub 2006 Aug 5. J Antimicrob Chemother. 2006. PMID: 16891628
154 results